Genome-Wide Identification and Analysis of the MAPK and MAPKK Gene Families in Potato (<i>Solanum tuberosum</i> L.)

Mitogen-activated protein kinase (MAPK) is an important component of the signal transduction pathway, which plays important roles in regulating plant growth and development, and abiotic stress. Potato (Solanum tuberosum L.) is one of the most popular tuber crops in the world. Genome-wide identification and analysis of the MAPK and MAPKK gene family in potato is not clear. A total of 20 MAPK genes and 8 MAPKK genes were identified in the potato genome. A conservative motif analysis showed that the MAPK protein contained a typical TxY phosphorylation site, and the MAPKK protein contained a conservative characteristic motif S/T-x5-S/T. Phylogenetic analysis showed that potato MAPK (mitogen-activated protein kinase) and MAPKK (mitogen-activated protein kinase kinase) were similar to Arabidopsis, including four groups of members A, B, C and D. Gene structure and promoter sequence analysis showed that all 28 gene family members of potato Solanum tuberosum MAPK (StMAPK) and StMAPKK have coding regions (CDS), and family members in the same group have similar intron and exon compositions, and that most cis-acting elements upstream of gene promoters elements have related to stress response. Chromosome location analysis found that MAPKs were unevenly distributed on 11 chromosomes, while MAPKKs were only distributed on chromosomes Chr. 03 and Chr. 12. Collinearity analysis showed that StMAPKK3 and StMAPKK6 have the same common ancestors among potato, pepper, and tomato. qRT-PCR results showed that the relative expressions of StMAPK14 and StMAPKK2 were significantly upregulated under low-temperature stress. These results could provide new insights into the characteristics and evolution of the StMAPK and StMAPKK gene family and facilitate further exploration of the molecular mechanism responsible for potato abiotic stress responses

A follow-up study on the recovery and reinfection of Omicron COVID-19 patients in Shanghai, China

ABSTRACTLimited follow-up data is available on the recovery of Omicron COVID-19 patients after acute illness. It is also critical to understand persistence of neutralizing antibody (NAb) and of T-cell mediated immunity and the role of hybrid immunity in preventing SARS-CoV-2 reinfection. This prospective cohort study included Omicron COVID-19 individuals from April to June 2022 in Shanghai, China, during a large epidemic caused by the Omicron BA.2 variant. A total of 8945 patients from three medical centres were included in the follow up programme from November 2022 to February 2023. Of 6412 individuals enrolled for the long COVID analysis, 605 (9.4%) individuals experienced at least one sequelae, mainly had fatigue and mental symptoms specific to Omicron BA.2 infection compared with other common respiratory tract infections. During the second-visit, 548 (12.1%) cases of Omicron reinfection were identified. Hybrid immunity with full and booster vaccination had reduced risk of SARS-CoV-2 reinfection by 0.29-fold (95% CI: 0.63–0.81) and 0.23-fold (95% CI: 0.68–0.87), respectively. For 469 participants willing to the hospital during the first visit, those who received full (72 [IQR, 36–156]) or booster (64 [IQR, 28–132]) vaccination had significantly higher neutralizing antibody titers than those with incomplete vaccination (36 [IQR, 16–79]). Moreover, non-reinfection cases had higher neutralizing antibody titers (64 [IQR, 28–152]) compared to reinfection cases (32 [IQR, 20–69])

A follow-up study on the recovery and reinfection of Omicron COVID-19 patients in Shanghai, China

Limited follow-up data is available on the recovery of Omicron COVID-19 patients after acute illness. It is also critical to understand persistence of neutralizing antibody (NAb) and of T-cell mediated immunity and the role of hybrid immunity in preventing SARS-CoV-2 reinfection. This prospective cohort study included Omicron COVID-19 individuals from April to June 2022 in Shanghai, China, during a large epidemic caused by the Omicron BA.2 variant. A total of 8945 patients from three medical centers were included in the follow up program from November, 2022 to February, 2023. Of 6412 individuals enrolled for the long COVID analysis, 605 (9.4%) individuals experienced at least one sequelae, mainly had fatigue and mental symptoms specific to Omicron BA.2 infection compared with other common respiratory tract infections. During the second-visit, 548 (12.1%) cases of Omicron reinfection were identified. Hybrid immunity with full and booster vaccination had reduced risk of SARS-CoV-2 reinfection by 0.29-fold (95% CI: 0.63 - 0.81) and 0.23-fold (95% CI: 0.68 - 0.87), respectively. For 469 participants willing to the hospital during the first visit, those who received full (72 [IQR, 36 - 156]) or booster (64 [IQR, 28 - 132]) vaccination had significantly higher neutralizing antibody titers than those with incomplete vaccination (36 [IQR, 16 - 79]). Moreover, non-reinfection cases had higher neutralizing antibody titers (64 [IQR, 28 - 152]) compared to reinfection cases (32 [IQR, 20 - 69]).</p